Monitor closing of the second PRV sale ($203M) expected this month and Q4 2025 results for restructuring charge impact and initial GENGLYCOS/FAYUVI launch revenue. The path to 2027 GAAP profitability depends on successful commercialization of two new gene therapies and sustained cost discipline.
Drugs in focus
RARE drug pipeline →Evkeeza
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
- Next catalyst
- None dated
What to watchEvkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.
Price Chart
Executive Summary
Ultragenyx completed the sale of a Rare Pediatric Disease PRV for $210M in gross proceeds (net ~$168M after NIH share), reported Q3 2026 total revenue of $173M (up 8% YoY from $160M) with a net loss of $118M ($1.16 per share) vs $180M loss a year ago, and announced a restructuring plan cutting ~20% of employees with ~$25M in charges. The PRV sale provides non-dilutive cash, but the restructuring signals cost pressure as the company transitions to commercial stage after two gene therapy approvals.
Key Financial Metrics
Key Facts
- Completed sale of GENGLYCOS PRV for $210M gross proceeds on October 30, 2026; 20% ($42M) payable to NIH, net ~$168M
- Q3 2026 total revenue $173M vs $160M YoY (up 8%); CRYSVITA $109M, DOJOLVI $30M, EVKEEZA $24M, MEPSEVII $10M
- Q3 2026 net loss $118M ($1.16 per share) vs $180M ($1.81) YoY; operating expenses $283M vs $331M
- Cash and marketable securities $401M as of Sep 30, 2026, down from $737M at Dec 31, 2025
- Restructuring plan: 20% workforce reduction, ~$25M in charges expected in Q4 2026, wind-down of GTX-102 (Angelman) and termination of UX701 (Wilson)
- Reaffirmed 2026 revenue guidance $730M-$760M (excl. new launches) and full-year GAAP profitability in 2027
- Second PRV (FAYUVI) under agreement for $203M expected to close later in November 2026
- R&D expenses cut 29% YoY to $154M in Q3; 2027 R&D guided to <$350M, SG&A <$375M
Financial Impact
PRV sale provides ~$350M net cash from two vouchers; restructuring targets at least 50% reduction in 2027 R&D vs 2025; Q3 revenue grew 8% YoY but cash burn remains significant
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| CRYSVITA | $109.0M | -2.7% |
| DOJOLVI | $30.0M | +25.0% |
| EVKEEZA | $24.0M | +41.2% |
| MEPSEVII | $10.0M | +42.9% |
Risk Factors
- Cash burn: cash dropped from $737M to $401M over nine months despite no major M&A; PRV proceeds are one-time
- Restructuring execution risk: 20% headcount reduction may disrupt commercial launches and R&D pipeline
- GENGLYCOS accelerated approval requires confirmatory studies; failure could lead to withdrawal
- GTX-102 (Angelman) wind-down and UX701 termination reduce pipeline optionality
- Stockholders' deficit grew to $376M from $80M at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-445342 |
| Document: 0001193125-26-445342-index.html | 0001193125-26-445342 |
| Document: 0001193125-26-445342.txt | 0001193125-26-445342 |
| 8-K Data (Synthetic) | 0001193125-26-445342 |
Track record
22 reports on RARE
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 Viewing No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers